Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade-Reference-Cited by-同舟云学术

Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade

Published:2019-02-18 Issue:3 Volume:20 Page:326-336
ISSN:1529-2908
Container-title:Nature Immunology
language:en
Short-container-title:Nat Immunol

Author:

Miller Brian C.^ORCID,Sen Debattama R.^ORCID,Al Abosy Rose^ORCID,Bi Kevin,Virkud Yamini V.,LaFleur Martin W.^ORCID,Yates Kathleen B.,Lako Ana,Felt Kristen,Naik Girish S.,Manos Michael,Gjini Evisa,Kuchroo Juhi R.,Ishizuka Jeffrey J.,Collier Jenna L.^ORCID,Griffin Gabriel K.,Maleri Seth,Comstock Dawn E.,Weiss Sarah A.,Brown Flavian D.,Panda Arpit,Zimmer Margaret D.,Manguso Robert T.,Hodi F. Stephen,Rodig Scott J.,Sharpe Arlene H.,Haining W. Nicholas^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Immunology,Immunology and Allergy

Link

http://www.nature.com/articles/s41590-019-0312-6.pdf

Reference50 articles.

1. Thommen, D. S. & Schumacher, T. N. T cell dysfunction in cancer. Cancer Cell. 33, 547–562 (2018).

2. Ahmadzadeh, M. et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 114, 1537–1544 (2009).

3. Zajac, A. J. et al. Viral immune evasion due to persistence of activated T cells without effector function. J. Exp. Med. 188, 2205–2213 (1998).

4. Moskophidis, D., Lechner, F., Pircher, H. & Zinkernagel, R. M. Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature 362, 758–761 (1993).

5. Wherry, E. J. T cell exhaustion. Nat. Immunol. 12, 492–499 (2011).

Cited by 1317 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in Vaccines for Melanoma;Hematology/Oncology Clinics of North America;2024-10

2. Combination of radiotherapy and PD-L1 blockade induces abscopal responses in EGFR-mutated lung cancer through activating CD8+ T cells;Translational Oncology;2024-10

3. Optimization of anti-TIM3 chimeric antigen receptor with CD8α spacer and TNFR-based costimulation for enhanced efficacy in AML therapy;Biomedicine & Pharmacotherapy;2024-10

4. Syndecan-1 inhibition promotes antitumor immune response and facilitates the efficacy of anti-PD1 checkpoint immunotherapy;Science Advances;2024-09-13

5. Expansion of tumor-reactive CD8 ⁺ T cell clonotypes occurs in the spleen in response to immune checkpoint blockade;Science Immunology;2024-09-13